Floatz logo

Molgramostim

Bronchiectasis

Savara Inc.protein_peptidePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

22 Active assets in the Bronchiectasis cohort.

Asset / SponsorPhaseRating
Ciprofloxacin
Centre Hospitalier Intercommunal Creteil
Phase 4BBB
Azithromycin
Assiut University
Phase 4BBB
Lipitor
University of Edinburgh
Phase 4BB
Theophylline
The First Affiliated Hospital of Guangzhou Medical University
Phase 4BB
Roflumilast
The University of Hong Kong
Phase 3BB

View all 50 →

Same molecule, other indications

Molgramostim is also rated in:

cystic fibrosisDormant
CCC
Indicative ·
55 / 100
View asset →
cutaneous melanomaDormant
CCC
Indicative ·
55 / 100
View asset →
Mycobacterium Infections, NontuberculousDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →